Biotechnology

Filter

Current filters:

None

Popular Filters

1980 to 2004 of 2379 results

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

KYTHERA Biopharma gets $33.3 million in payments from Bayer

07-06-2012

Privately-held US biotech firm KYTHERA Biopharmaceuticals says it has received a $15.8 million payment…

BayerBiotechnologyFinancialKYTHERA BiopharmaceuticalsLicensingPharmaceuticalResearch

Reimbursement outlook for DMT Alzheimer's therapies in Europe

06-06-2012

Emerging potentially disease-modifying therapies (DMTs) for Alzheimer's disease will likely be reimbursed…

BiotechnologyEuropeMarkets & MarketingNeurologicalPharmaceuticalPricing

UK pharma industry head fears for future of UK medical research

06-06-2012

The UK government is too focused on encouraging "breakthrough drugs" at the expense of significant gains…

BiotechnologyEuropePharmaceuticalPoliticsPricingResearch

Enterologics aims to produce Rx biotherapeutics for GI diseases

05-06-2012

USA-based biotech firm Enterologics (OTCBB: ELGO.OB), which is focussed on the development of live biotherapeutic…

BiotechnologyEnterologicsGastro-intestinalsNorth AmericaResearch

Zacks analysts view progress of GSK bid for Human Genome Sciences

05-06-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) recently announced that the waiting period with respect to…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Onyx Pharma links with Texas MD Anderson Cancer Center on research

05-06-2012

US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center…

BiotechnologycarfilzomibOncologyOnyx PharmaceuticalsoprozomibResearch

Rindopepimut likely to be Rxed by 36% of surveyed US oncologists for GMB patients

05-06-2012

US oncologists surveyed by advisory firm Decision Resources indicate that they would prescribe the emerging…

BiotechnologyCelldex TherapeuticsMarkets & MarketingNorth AmericaOncologyPharmaceuticalrindopepimut

NicOx drops its option to take full ownership of Altacor

04-06-2012

French biotechnology firm NicOx (NYSE Euronext Paris: COX) said last Friday that its board of directors…

AltacorBiotechnologyMergers & AcquisitionsNicOxOphthalmics

EMA boosts EU transparency with on-line publication of suspected side effect reports

31-05-2012

The European Medicines Agency yesterday began publishing suspected side effect reports for medicines…

BiotechnologyEuropePharmaceuticalRegulation

Alnylam's RSV drug candidate misses primary endpoint in Ph IIb

31-05-2012

Leading USA-based RNAi therapeutics firm Alnylam Pharmaceuticals (Nasdaq: ALNY) yesterday announced disappointing…

Alnylam PharmaceuticalsBiotechnologyResearchRespiratory and Pulmonary

BioAlliance's Sitavig NDA "receivable" by US FDA

30-05-2012

French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the receivability of its Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyNorth AmericaRegulationSitavigSitavir

Expanded Access Program for enzalutamide agreed with US FDA

30-05-2012

The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas…

Astellas PharmaBiotechnologyenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

US legislation could block public access to drug safety information, claim consumer groups

30-05-2012

A provision in the Food and Drug Administration Reform Act that would block public access to potentially…

BiotechnologyNorth AmericaPharmaceuticalPoliticsRegulation

Genentech links up with Ensemble Thera for macrocyclic drug candidates discovery

30-05-2012

Swiss drug major Roche's (ROG: SIX) subsidiary Genentech has initiated a drug discovery collaboration…

BiotechnologyEnsemble TherapeuticsGenentechLicensingResearchRoche

Rainbow BioSci seeks to develop treatment for traumatic brain injury

29-05-2012

USA-based Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp (OTCBB: RBCC) revealed yesterday…

Amarantus BioSciencesBiotechnologyLicensingNeurologicalRainbow Biosciences

UK health and life sciences group agrees new clinical trials transparency principles

28-05-2012

The Ethical Standards in Health and Life Sciences Group (ESHLSG), a partnership including the Association…

BiotechnologyEuropePharmaceuticalRegulationResearch

EMA orphan drug committee makes 16 recommendations at May meeting

28-05-2012

The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a total of 16…

Alexion PharmaceuticalsBiotechnologyeculizumabEuropePharmaceuticalRare diseasesRegulation

1980 to 2004 of 2379 results

Back to top